Myriad Genetics Announces Flurizan Phase 2 Results Presentation Conference Call

SALT LAKE CITY, June 15 -- Myriad Genetics, Inc. (Nasdaq: MYGN), has arranged a conference call with management to provide a discussion of the Phase 2 data presentation at the Alzheimer's Association International Conference on Prevention of Dementia, scheduled for June 20, 2005. Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. and Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. will host the call with Professor Gordon Wilcock, Principal Investigator of the Phase 2 trial of Flurizan in Alzheimer's disease.

CALL DATE: June 21, 2005
TIME: 10:00 a.m. Eastern
DOMESTIC DIAL-IN: (888) 589-2820
INT'L DIAL-IN: (706) 634-2173

Please call in approximately 10 minutes before the call is scheduled to begin.

A related press release will be issued at 7:30 a.m. on June 20th.

Replay of the call will be available beginning two hours after the call through June 28th, by dialing (800) 642-1687 or (706) 645-9291.

An audio Web cast of the call will be available through a link on Myriad's home page at www.myriad.com.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.